Pair page
Bromantane with Cerebrolysin
Mechanism-tag overlap and published literature for Bromantane and Cerebrolysin, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
actoprotector-adamantane-derivative
neurotrophic-brain-bioregulator
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Bromantane and Cerebrolysin have published these mechanism-level observations. Not a co-administration recommendation.
Cerebrolysin provides broad neurotrophic support (NGF / BDNF / GDNF mimetic) via IV cycles; Bromantane provides sustained dopaminergic synthesis capacity. Complementary in post-stroke / post-concussion recovery protocols where both mechanisms are relevant.
Quick facts
Bromantane
Cerebrolysin
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2009 | Bromantane | Badyshtov BA, Makhnycheva AL, Kolik LG, Seredenin SB. Efficacy and safety of ladasten for treatment of asthenic disorders. Results of clinical trials. Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(5):24-28. (Phase III supporting Russian Ladasten approval.) | human trial, Phase 3 |
| 2006 | Bromantane | Vakhitova IuV, Iamidanov RS, Vakhitov VA, Seredenin SB. The effect of ladasten on gene expression in the rat brain. Mol Biol (Mosk). 2006;40(3):385-391. PMID: 16837899. PMID 16837899 | preclinical, in vivo |
| 1995 | Bromantane | Grekhova TV, Gaĭnetdinov RR, Sotnikova TD, Krasnykh LM, Kudrin VS, Sergeeva SA, Morozov IS, Rayevskiĭ KS. The effect of bromantane, a new immunostimulant and actoprotective preparation, on the release and metabolism of dopamine in the dorsal striatum of freely-moving rats. An in… | preclinical, in vivo |
| 1995 | Bromantane | Kudrin VS, Sergeeva SA, Krasnykh LM, Miroshnichenko II, Grekhova TV, Gainetdinov RR. The effect of bromantan on the dopamin- and serotoninergic systems of the rat brain. Eksp Klin Farmakol. 1995;58(4):8-11. PMID: 8555937. (Russian-language primary preclinical paper on neurotrans… PMID 8555937 | preclinical, in vivo |
| 2001 | Bromantane | Spasov AA, Bugaeva LI, Iezhitsa IN. Toxicological profile of adamantane derivatives. Eksp Klin Farmakol. 2001;64(2):77-80. (Toxicological characterization of the adamantane-derivative class.) | mechanism / discovery |
| 2012 | Bromantane | Oliynyk S, Oh S. The pharmacology of actoprotectors: practical application for improvement of mental and physical performance. Biomol Ther (Seoul). 2012;20(5):446-456. PMID: 24009833. (English-language review of the actoprotector class with bromantane as central example.) PMID 24009833 | review |
| 2004 | Bromantane | World Anti-Doping Agency. Prohibited List. International Standard. S6 Stimulants: bromantan. WADA. Various editions 2004–2026. (Continuous inclusion on the prohibited list since inception.) | regulatory / registry |
| 2008 | Bromantane | Voronina TA, Molodavkin GM, Sergeeva SA, Borliakov LM. Analysis of the neurophysiological mechanisms of anxiolytic effects of ladasten and afobazol. Eksp Klin Farmakol. 2008;71(3):3-7. PMID: 18651609. PMID 18651609 | research article |
| 2002 | Bromantane | Yakimovskii AF, Varshavskaya VM. Experimental analysis of psychopharmacological activity of bromantane. Bull Exp Biol Med. 2002;134(1):60-62. PMID: 12459869. PMID 12459869 | research article |
| 2001 | Bromantane | Morozov IS, Ivanova IA, Sergeeva SA, Petrov VI. Bromantan - a new immunostimulant and psychostimulant of the actoprotector series. Eksp Klin Farmakol. 2001;64(2):44-48. PMID: 11396112. PMID 11396112 | research article |
| 2021 | Cerebrolysin | Vester JC, Buzoianu AD, Florian SI, Hömberg V, Kim SH, Lee TMC, Matula C, Poon WS, von Steinbüchel N, Strilciuc S, von Wild K, Muresanu D. Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurol Sci. 2021;42(2):… PMID 33620612 | meta-analysis |
| 2018 | Cerebrolysin | Bornstein NM, Guekht A, Vester J, Heiss WD, Gusev E, Hömberg V, Rahlfs VW, Bajenaru O, Popescu BO, Muresanu D. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurol Sci. 2018;39(4):629-640. PMID: 29248999. PMID 29248999 | meta-analysis |
| 2015 | Cerebrolysin | Gauthier S, Proaño JV, Jia J, Froelich L, Vester JC, Doppler E. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. Dement Geriatr Cogn Disord. 2015;39(5-6):332-347. PMID: 25832905. PMID 25832905 | meta-analysis |
| 2020 | Cerebrolysin | Poon W, Vos P, Muresanu D, Vester J, von Wild K, Hömberg V, et al. Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I — a randomized, placebo-controlled, double-blind, Asian-Pacific trial. Neurol Sci. 2020;41(2):281-293. PMID: 31494820. PMID 31494820 | human trial |
| 2020 | Cerebrolysin | Woo PYM, Ho JWK, Ko NMW, Li RPT, Jian L, Chu ACH, Kwan MCL, Chan Y, Wong AKS, Wong HT, Chan KY, Kwok JCK. Randomized, placebo-controlled, double-blind, pilot trial to investigate safety and efficacy of Cerebrolysin in patients with aneurysmal subarachnoid hemorrhage. BMC Neurol.… PMID 33143640 | human trial |
| 2017 | Cerebrolysin | Gharagozli K, Harandi AA, Houshmand S, Akbari N, Muresanu DF, Vester J, Winter S, Moessler H. Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial. J Med Life. 20… PMID 29075343 | human trial |
| 2016 | Cerebrolysin | Muresanu DF, Heiss WD, Hoemberg V, Bajenaru O, Popescu CD, Vester JC, Rahlfs VW, Doppler E, Meier D, Moessler H, Guekht A. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. 2016;47(1):151-159. PMID: 26564102. PMID 26564102 | human trial |
| 2016 | Cerebrolysin | Hassanein SM, Deifalla SM, El-Houssinie M, Mokbel SA. Safety and Efficacy of Cerebrolysin in Infants with Communication Defects due to Severe Perinatal Brain Insult: A Randomized Controlled Clinical Trial. J Clin Neurol. 2016;12(1):79-84. PMID: 26365023. PMID 26365023 | human trial |
| 2012 | Cerebrolysin | Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z; Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012;43(3):630-636. PM… PMID 22282884 | human trial |
| 2010 | Cerebrolysin | Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of Cerebrolysin in patients with acute ischaemic stroke in Asia — CASTA. Int J Stroke. 2010;5(4):310-313. PMID: 19765131. PMID 19765131 | human trial |
| 2005 | Cerebrolysin | Ladurner G, Kalvach P, Moessler H; Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. J Neural Transm (Vienna). 2005;112(3):415-428. PMID: 15583955. PMID 15583955 | human trial |
| 2023 | Cerebrolysin | Rejdak K, Sienkiewicz-Jarosz H, Bienkowski P, Alvarez A. Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin. Med Res Rev. 2023;43(5):1668-1700. PMID: 37052231. PMID 37052231 | human study |
Related pair pages
More research context
Frequently asked
Have Bromantane and Cerebrolysin been studied together?
Researchers have published mechanistic-level co-administration discussion of Bromantane and Cerebrolysin. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Bromantane and Cerebrolysin share?
Bromantane and Cerebrolysin do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Bromantane and Cerebrolysin?
Bromantane: Not approved (US). Cerebrolysin: Not approved (US). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Bromantane and Cerebrolysin?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Bromantane profile and the Cerebrolysin profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026